What is the main purpose of this 10-Q filing?

This 10-Q filing serves as a mandatory quarterly report by Bristol-Myers Squibb Co. to the U.S. Securities and Exchange Commission (SEC). It provides an update on the company's financial performance and condition for the period ending September 29, 1998.

What kind of financial information can I expect from a 10-Q filing?

A full 10-Q filing typically includes unaudited financial statements (income statement, balance sheet, cash flow statement), notes to the financial statements, and Management's Discussion and Analysis (MD&A) of financial condition and results of operations. The MD&A is particularly important for understanding the business trends and significant factors affecting the company's performance.

Where can I find the detailed financial results for BMY from this period?

The provided text is a directory listing and does not contain the actual financial data. To get the detailed financial results, you would need to access the complete 10-Q filing document, likely through the SEC's EDGAR database or the company's investor relations website, if available for historical filings.

What are the key risks or opportunities for BMY based on this filing?

This specific excerpt does not provide enough detail to identify key risks or opportunities. Investors must review the full Management's Discussion and Analysis section within the complete 10-Q filing to understand management's perspective on significant factors affecting the company's business, financial condition, and results of operations.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q3 FY1998

Summary

Bristol-Myers Squibb Co. (BMY) filed its quarterly report for the period ending September 29, 1998. While the provided filing snippet does not contain detailed financial statements or management discussion, it indicates a routine disclosure under SEC regulations. Investors should note that this filing represents the company's operational and financial status as of the third quarter of 1998. For a comprehensive understanding, investors would need to access the full 10-Q document, which would typically include detailed income statements, balance sheets, cash flow statements, and the Management's Discussion and Analysis of Financial Condition and Results of Operations. This section is crucial for insights into revenue trends, profitability, debt levels, and any significant events or risks impacting the company's performance. Without this detailed information, it is impossible to provide specific financial performance metrics or strategic commentary.

Key Highlights

1Company: Bristol-Myers Squibb Co. (BMY)
2Filing Type: 10-Q Quarterly Report
3Period End Date: September 29, 1998
4Filing Date: November 15, 1998
5Indicates routine SEC disclosure for the third quarter of 1998.
6Requires access to the full report for detailed financial and operational analysis.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 1998

Summary

Key Highlights

Frequently Asked Questions